The global mammalian polyclonal IgG antibody market size reached USD 1.14 billion in 2024. Looking forward, the research expects the market to reach USD 1.70 billion by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033. The market growth is driven by the increasing collaborations between research institutes and industry players, the rising focus on monoclonal and polyclonal antibody research, the expanding global healthcare infrastructure, the growing use in autoimmune disease treatment, the escalating adoption of recombinant antibodies, and significant growth of the contract research organization (CRO) industry.
Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations.
Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.
As these conditions require more sophisticated diagnostics and management, mammalian polyclonal IgG antibodies are commonly used in immunoassays, directed therapy, and modulation of the immune system. Due to the persistent growth in chronic medical conditions, the prevalent need for relative antibody-based and other solutions contributes to the further advancement of the market.
Additionally, advancements in antibody engineering and an increased focus on personalized medicine further enhance the adoption of therapeutic antibodies. This rising demand fuels research, development, and production of mammalian polyclonal IgG antibodies, contributing to significant market growth and expanding their applications in modern healthcare.
Continual advancements in biopharmaceutical technologies, such as antibody engineering, and the push for biologics and biosimilars are also driving the demand for these antibodies, leading to increased production and wider applications for these antibodies. Additionally, the industry's focus on personalized medicine and precision therapies increases the need for high-quality antibodies, further providing a boost to the market.
Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations.
Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.
Mammalian Polyclonal IgG Antibody Market Trends:
Increasing prevalence of chronic diseases
The increasing number of cases of chronic diseases, such as cancer, cardiovascular disease, and autoimmune diseases, is a major factor leading to the expansion of the mammalian polyclonal IgG antibody market size. For instance, the prevalence of individuals aged 25 and older with at least one chronic disease, based on 28 recorded diagnoses in general practice, rose from 34.9% in 2004 to 41.8% in 2011, reflecting a statistically significant increase of 6.9 percentage points during that period.As these conditions require more sophisticated diagnostics and management, mammalian polyclonal IgG antibodies are commonly used in immunoassays, directed therapy, and modulation of the immune system. Due to the persistent growth in chronic medical conditions, the prevalent need for relative antibody-based and other solutions contributes to the further advancement of the market.
Rising demand for therapeutic antibodies
The rising demand for therapeutic antibodies is a key factor augmenting the mammalian polyclonal IgG antibody market share. Therapeutic antibodies are increasingly used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, due to their high specificity and ability to target disease-causing agents effectively. As biopharmaceutical companies develop more antibody-based therapies, the demand for polyclonal IgG antibodies, which are essential in immune response modulation and research applications, is growing.Additionally, advancements in antibody engineering and an increased focus on personalized medicine further enhance the adoption of therapeutic antibodies. This rising demand fuels research, development, and production of mammalian polyclonal IgG antibodies, contributing to significant market growth and expanding their applications in modern healthcare.
Significant growth in the biotechnology and pharmaceutical industries
The growth of the biotechnology and pharmaceutical industries is a significant driver of the market. As these industries expand, there has been increasing investments in research and development (R&D) activities involving innovative therapeutic and diagnostic solutions. Polyclonal IgG antibodies play a critical role in drug discovery, disease diagnostics, and therapeutic development, especially for complex diseases like cancer and autoimmune disorders.Continual advancements in biopharmaceutical technologies, such as antibody engineering, and the push for biologics and biosimilars are also driving the demand for these antibodies, leading to increased production and wider applications for these antibodies. Additionally, the industry's focus on personalized medicine and precision therapies increases the need for high-quality antibodies, further providing a boost to the market.
Key Market Segmentation:
The research provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on type, product, application, and end use.Breakup by Type:
- Goat
- Rabbit
- Horse
- Mouse
- Other.
Breakup by Product:
- Cardiac Markers
- Metabolic Markers
- Renal Markers
- Other.
Breakup by Application:
- ELISA
- Immunoturbidimetry
- Immunoelectrophoresis
- Antibody Identification
- Immunohistochemistry
- Immunocytochemistry
- Western Blottin.
Breakup by End Use:
- Hospitals
- Diagnostic Centers
- Academic and Research Institute.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Afric.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global mammalian polyclonal IgG antibody market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:- Abbiotec Inc.
- Abcam plc
- Bio-Rad Laboratories Inc.
- Cell Signaling Technology Inc.
- Creative Diagnostics
- Elabscience Biotechnology Inc.
- Geno Technology Inc.
- Merck KGaA
- Proteintech Group Inc.
- STEMCELL Technologies Inc.
- Thermo Fisher Scientific Inc.
Key Questions Answered in This Report
- How big is the global mammalian polyclonal IgG antibody market?
- What is the expected growth rate of the global mammalian polyclonal IgG antibody market during 2025-2033?
- What are the key factors driving the global mammalian polyclonal IgG antibody market?
- What has been the impact of COVID-19 on the global mammalian polyclonal IgG antibody market?
- What is the breakup of the global mammalian polyclonal IgG antibody market based on the type?
- What is the breakup of the global mammalian polyclonal IgG antibody market based on the product?
- What is the breakup of the global mammalian polyclonal IgG antibody market based on the application?
- What is the breakup of the global mammalian polyclonal IgG antibody market based on the end use?
- What are the key regions in the global mammalian polyclonal IgG antibody market?
- Who are the key players/companies in the global mammalian polyclonal IgG antibody market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Mammalian Polyclonal IgG Antibody Market
6 Market Breakup by Type
7 Market Breakup by Product
8 Market Breakup by Application
9 Market Breakup by End Use
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbiotec Inc.
- Abcam plc
- Bio-Rad Laboratories Inc.
- Cell Signaling Technology Inc.
- Creative Diagnostics
- Elabscience Biotechnology Inc.
- Geno Technology Inc.
- Merck KGaA
- Proteintech Group Inc.
- STEMCELL Technologies Inc.
- Thermo Fisher Scientific Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | June 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.14 Billion |
| Forecasted Market Value ( USD | $ 1.7 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
